Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis

I Roos; S Hughes; G McDonnell; CB Malpas; S Sharmin; C Boz; R Alroughani; S Ozakbas; K Buzzard; O Skibina; A Van Der Walt; H Butzkueven; J Lechner-Scott; J Kuhle; M Terzi; G Laureys; L Van Hijfte; N John; P Grammond; F Grand'Maison; A Soysal; AV Jensen; PV Rasmussen; KB Svendsen; I Barzinji; HH Nielsen; T Sejbæk; S Prakash; MLM Stilund; A Weglewski; NM Issa; M Kant; F Sellebjerg; O Gray; M Magyari; T Kalincik

Journal article

Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis

I Roos, S Hughes, G McDonnell, CB Malpas, S Sharmin, C Boz, R Alroughani, S Ozakbas, K Buzzard, O Skibina, A Van Der Walt, H Butzkueven, J Lechner-Scott, J Kuhle, M Terzi, G Laureys, L Van Hijfte, N John, P Grammond, F Grand'Maison Show all

JAMA Neurology | Published : 2023

DOI: 10.1001/jamaneurol.2023.1625

Download PDF

Abstract

Importance: Ocrelizumab, a humanized monoclonal antibody targeted against CD20+ B cells, reduces the frequency of relapses by 46% and disability worsening by 40% compared with interferon beta 1a in relapsing-remitting multiple sclerosis (MS). Rituximab, a chimeric monoclonal anti-CD20 agent, is often prescribed as an off-label alternative to ocrelizumab. Objective: To evaluate whether the effectiveness of rituximab is noninferior to ocrelizumab in relapsing-remitting MS. Design, Setting, and Participants: This was an observational cohort study conducted between January 2015 and March 2021. Patients were included in the treatment group for the duration of study therapy and were recruited from..

View full abstract

University of Melbourne Researchers

Izanne Roos Author

Charles Malpas Author

Sifat Sharmin Author

Tomas Kalincik Author

Related Projects (3)

PRECISION TREATMENT FOR MULTIPLE SCLEROSIS: MAXIMISING THE EFFECT OF IMMUNOMODULATORY THERAPY

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

BIOMARKERS TO PREVENT DISABILITY IN MULTIPLE SCLEROSIS

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

Grants

Awarded by National Health and Medical Research Council

Funding Acknowledgements

This study was supported by grants 1140766, 1129189, and 1157717 from the National Health and Medical Research Council; a postdoctoral fellowship grant from MS Australia (Dr Roos); and Biogen, Novartis, Merck, Roche, Teva, and Sanofi Genzyme (MSBase Foundation).